MEDO.ai receives FDA approval to automatically detect hip dysplasia, preventing the leading cause of early hip osteoarthritis and hip replacement surgery EDMONTON, Alberta, June 16, 2020 (GLOBE NEWSWIRE) -- MEDO.ai, an artificial intelligence technology start-up company dual headquartered in Edmonton, Canada, and Singapore, is pleased to...